Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection

被引:88
作者
Aravagiri, M [1 ]
Ames, D [1 ]
Wirshing, WC [1 ]
Marder, SR [1 ]
机构
[1] UNIV CALIF LOS ANGELES,PSYCHOPHARMACOL UNIT,LOS ANGELES,CA
关键词
antipsychotics; electrochemical detection; high-performance liquid chromatography; olanzapine; plasma level-dose relationship; plasma level monitoring; schizophrenic patients;
D O I
10.1097/00007691-199706000-00011
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A sensitive high-performance liquid chromatography method with electrochemical detection for the determination of olanzapine in human plasma is described. Olanzapine from plasma samples was isolated by a simple one-step liquid-liquid extraction with 15% methylene chloride in pentane with an extraction recovery of approximately 94% of the total olanzapine in plasma. The compound was separated on a cyano column. Under the conditions described, commonly coadministered drugs and other common antipsychotic drugs did not interfere with the analysis of olanzapine. The lower. limit of determination of the assay was 0.25 ng of olanzapine per ml when 1 ml of plasma was used for the analysis. The interassay and intraassay variance was (CV%) less than 10%. The standard curve was linear within the range of 0.25 to 50 ng/ml of olanzapine. This method has been used for the determination of plasma levels of olanzapine in patients with schizophrenia who were treated with daily oral doses of 10, 15, and 20 ng of olanzapine. The results indicate that the plasma level of olanzapine increases linearly with the administered daily oral dose (r = 0.6889, p = 0.01).
引用
收藏
页码:307 / 313
页数:7
相关论文
共 13 条
  • [1] Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
    Beasley, CM
    Sanger, T
    Satterlee, W
    Tollefson, G
    Tran, P
    Hamilton, S
    Green, A
    Dott, S
    Pfister, G
    Roxas, L
    Small, J
    Thomas, M
    Ames, D
    Schooler, N
    Baker, R
    Levine, R
    Fabre, L
    Friedel, R
    Safferman, A
    Lieberman, J
    Stahl, S
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 159 - 167
  • [2] CLINICAL EFFICACY OF SEROTONIN-DOPAMINE ANTAGONISTS RELATIVE TO CLASSIC NEUROLEPTICS
    BORISON, RL
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) : S24 - S29
  • [3] Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats
    Bymaster, FP
    HemrickLuecke, SK
    Perry, KW
    Fuller, RW
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 87 - 94
  • [4] CLOZAPINE - NEUROLEPTIC-INDUCED EPS AND TARDIVE-DYSKINESIA
    CASEY, DE
    [J]. PSYCHOPHARMACOLOGY, 1989, 99 : S47 - S53
  • [5] ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
    CATLOW, JT
    BARTON, RD
    CLEMENS, M
    GILLESPIE, TA
    GOODWIN, M
    SWANSON, SP
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01): : 85 - 90
  • [6] DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS
    CREESE, I
    BURT, DR
    SNYDER, SH
    [J]. SCIENCE, 1976, 192 (4238) : 481 - 483
  • [7] GERLACH J, 1995, INT CLIN PSYCHOPHARM, V10
  • [8] MOORE NA, 1992, J PHARMACOL EXP THER, V262, P545
  • [9] Clozapine versus typical antipsychotics - A retro- and prospective study of extrapyramidal side effects
    Peacock, L
    Solgaard, T
    Lublin, H
    Gerlach, J
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 188 - 196
  • [10] SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261